#Japan #Tokyo #LifeSphere #ArisGlobal #EPS Corporation

EPS Corporation Selects ArisGlobal's LifeSphere® MultiVigilance

In a significant move towards enhancing pharmacovigilance capabilities, EPS Corporation, the leading contract research organization (CRO) in Japan, has announced its partnership with ArisGlobal. ArisGlobal is renowned for its innovative AI-driven solutions in life sciences, particularly through its product, LifeSphere MultiVigilance. The collaboration is aimed at modernizing EPS's approach to managing safety cases for its sponsor partners, ensuring a more efficient and compliant process.

Modernizing Pharmacovigilance

Pharmacovigilance involves the assessment and monitoring of the safety of pharmaceutical products. In today's complex regulatory landscape, efficiency and accuracy in processing safety data are more critical than ever. With the implementation of LifeSphere MultiVigilance, EPS aims to enhance its operational consistency, aligning with the requirements of Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and global standards. ArisGlobal's state-of-the-art technology is designed to streamline case processing and facilitate automation, which will be essential as the volume of cases continues to grow.

By adopting this advanced system, EPS Corporation is positioning itself to handle increasing case volumes and provide faster, higher-quality services to its clients. The capability of LifeSphere MultiVigilance to support multilingual sponsor bases and adapt to diverse reporting requirements is particularly valuable, given the global nature of today's pharmaceutical landscape.

Commitment to Quality and Compliance

The partnership reflects a broader trend among CROs, both in Japan and worldwide, where a shift towards more automated and modern pharmacovigilance systems is apparent. EPS Corporation is set to centralize its case processing under the LifeSphere MultiVigilance platform, which is expected to significantly reduce manual workloads. This strategic advancement is anticipated to improve the global consistency of reporting, ultimately delivering enhanced value to its sponsor partners as they navigate increasingly complicated safety requirements.

Zhiyi Chen, Senior Vice President for APAC at ArisGlobal, emphasized the importance of this transformation, stating, "EPS is demonstrating how CROs can scale effectively by modernizing core safety operations. We're proud to support their transformation and look forward to continuing innovation together."

The adoption of LifeSphere MultiVigilance by EPS is not merely a technological upgrade; it signifies a commitment to delivering top-notch pharmacovigilance services. Both ArisGlobal and EPS are dedicated to advancing healthcare through solutions that prioritize accuracy, speed, and compliance, thus strengthening their operational models.

About EPS Corporation and ArisGlobal

EPS Corporation holds a prominent position as Japan's largest CRO, providing critical support to pharmaceutical and biotech companies with a wide array of services, including clinical development and regulatory operations. The company is steadfast in its mission to promote healthcare advancements through collaboration and efficiency.

On the other hand, ArisGlobal, headquartered in the United States, is at the forefront of transforming how life sciences companies progress in developing new therapeutics and launching them in the market. With regional offices in Europe, India, Japan, and China, ArisGlobal continually strives for innovation in pharmacovigilance and other aspects of life sciences. Together, EPS Corporation and ArisGlobal are set to make significant strides in ensuring patient safety and effective healthcare practices.